Total Funding
29
1
Total FundingPost-IPO Equity raised
Growth Score
-3 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
4171438
Aeolus Pharmaceuticals develops lead compound, AEOL-10150, as a treatment for the pulmonary and delayed effects of acute radiation exposure.
Christopher Stanley: VP, Operations
About the Company
Aeolus Pharmaceuticals is developing its lead compound, AEOL-10150, as a treatment for the pulmonary and delayed effects of acute radiation exposure (“Lung-ARS” and “DEARE”). The Company’s development work is funded under a five year, $118 million, cost-plus contract with the Biomedical Advanced Research and Development Authority (“BARDA”), a
division of the U.S. Department of Health and Human Services. BARDA is the Federal agency in charge of contracting for advanced development of drugs to treat radiological, biological and chemical threats for the civilian population. BARDA also manages the $2.8BB Special Reserve Fund for the purchase of these drugs for the U.S. Strategic National Stockpile.
